Craif announces joint research results on urological cancers (renal cell carcinoma, prostate cancer, urothelial carcinoma) at EAU 2026 (European Association of Urology)
NQ Score
100/100
AI Summary (NQ-processed)
Bio-AI startup Craif Inc. announced joint research results on urological cancers at EAU 2026 in London. The study, conducted with Keio University School of Medicine, focused on machine learning-based analysis of urinary exosomal microRNA for detection, prognostic evaluation, and immune profiling of renal cell carcinoma, prostate cancer, and urothelial carcinoma. The developed technology showed high screening accuracy and potential utility in prognosis and tumor immune status assessment.
AI analysis data is not yet available.